Scientific article

Transplantation de pancréas et d'ilôts de Langerhans: le point en 2009 et le futur

Published inRevue médicale suisse, vol. 5, no. 206, p. 1266-1270,1272
Publication date2009

Type 1 diabetes currently affects 15,000 patients in Switzerland with a rising incidence worldwide. Pancreas or islet of Langerhans transplantation are alternatives to intensive insulin treatment, which decreases long-term complications at the cost of an increase of severe hyoglycemia. Pancreas transplantation, indicated mainly to diabetic patients with simultaneous kidney transplantation, has a high success rate, but is accompanied by high morbidity due to general surgery. Islet transplantation, a cell-therapy for type 1 diabetes, is in full development. It is mainly indicated as islet transplant alone in patients suffering from brittle diabetes, and is associated with a very low risk due to minimally invasive technique, but a lower rate of long-term success. New potential sources of beta cell replacement are beta-cell lines, stem cells and xenotransplantation.

  • Diabetes Mellitus, Type 1/surgery
  • Humans
  • Islets of Langerhans Transplantation
  • Pancreas Transplantation
Citation (ISO format)
NICLAUSS, Nadja et al. Transplantation de pancréas et d’ilôts de Langerhans: le point en 2009 et le futur. In: Revue médicale suisse, 2009, vol. 5, n° 206, p. 1266–1270,1272.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation10/31/2013 1:18:00 PM
First validation10/31/2013 1:18:00 PM
Update time03/14/2023 8:45:10 PM
Status update03/14/2023 8:45:10 PM
Last indexation08/29/2023 8:21:43 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack